person · Reporting owner

PALMISANO ROBERT J

Disclosed activity across 4 companies

Tapewire entity: 36462
SEC CIK: 0001138646

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AEON Biopharma, Inc.AEON · Entity 7859	Director	June 17, 2026	June 22, 2026
RxSight, Inc.RXST · Entity 1226	Director	June 17, 2026	June 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AEON Biopharma, Inc.

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	258,705	Reported balance After 2026-06-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 222,684 · Balance 258,705 F1: Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.

RxSight, Inc.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	78,076	Reported balance After 2026-06-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 37,037 · Balance 78,076 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AVEDRO INC

Report date November 21, 2019 · Filed November 25, 2019

Section 16 reporting ended · disclosed 2019-11-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2019-11-21 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-11-21 · Disposition to issuer · Disposed 37,733 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F2: The reportable securities are directly owned by the Robert J. Palmisano 2010 Trust (the "Trust"). The Reporting Person is the trustee of the Trust.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2029-01-08	IndirectSee footnote	Reported balance After 2019-11-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-21 · Disposition to issuer · Disposed 8,314 · Balance 0 F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. F2: The reportable securities are directly owned by the Robert J. Palmisano 2010 Trust (the "Trust"). The Reporting Person is the trustee of the Trust.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.80 · Expires 2028-01-30	Direct	Reported balance After 2019-11-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-21 · Disposition to issuer · Disposed 1,081 · Balance 0 F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2028-09-13	Direct	Reported balance After 2019-11-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-21 · Disposition to issuer · Disposed 28,089 · Balance 0 F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2027-06-26	Direct	Reported balance After 2019-11-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-21 · Disposition to issuer · Disposed 12,628 · Balance 0 F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.69 · Expires 2028-07-17	Direct	Reported balance After 2019-11-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-21 · Disposition to issuer · Disposed 10,224 · Balance 0 F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-11-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-21 · Disposition to issuer · Disposed 3,005 · Balance 0 F4: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share.

F2: The reportable securities are directly owned by the Robert J. Palmisano 2010 Trust (the "Trust"). The Reporting Person is the trustee of the Trust.

F3: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer.

F4: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F5: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU.

Wright Medical Group N.V.

Report date November 11, 2020 · Filed November 13, 2020

Section 16 reporting ended · disclosed 2020-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative	Direct	244,362	Reported balance After 2020-11-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-11-11 · Other · Disposed 863,885 · Balance 244,362 F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 863,885 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). F2: Includes 83,646 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 160,716 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See notes (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer.
Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative	Direct	95,975	Reported balance After 2020-11-11 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2020-11-11 · Disposition to issuer · Disposed 148,387 · Balance 95,975 F3: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer. F4: Includes 83,646 Shares issuable upon vesting of the Wright RSUs and 12,329 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer.
Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2020-11-11 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2020-11-11 · Disposition to issuer · Disposed 95,975 · Balance 0 F5: See Exhibit 99.1
Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative	Direct	229,054	Reported balance After 2020-11-11 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2020-11-11 · Grant · Acquired 229,054 · Balance 229,054 F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes.
Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2020-11-11 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2020-11-11 · Disposition to issuer · Disposed 229,054 · Balance 0 F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.84 · Expires 2029-07-26	Direct	0	Reported balance After 2020-11-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-11 · Disposition to issuer · Disposed 181,429 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2028-07-24	Direct	0	Reported balance After 2020-11-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-11-11 · Disposition to issuer · Disposed 149,008 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.86 · Expires 2027-07-25	Direct	0	Reported balance After 2020-11-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-11-11 · Disposition to issuer · Disposed 137,373 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.42 · Expires 2026-07-19	Direct	0	Reported balance After 2020-11-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-11-11 · Disposition to issuer · Disposed 271,076 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.62 · Expires 2025-10-13	Direct	0	Reported balance After 2020-11-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-11-11 · Disposition to issuer · Disposed 598,702 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.62 · Expires 2025-10-13	Direct	0	Reported balance After 2020-11-11 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-11-11 · Disposition to issuer · Disposed 239,481 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.06 · Expires 2024-05-13	Direct	0	Reported balance After 2020-11-11 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2020-11-11 · Disposition to issuer · Disposed 129,462 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.14 · Expires 2024-04-01	Direct	0	Reported balance After 2020-11-11 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2020-11-11 · Disposition to issuer · Disposed 7,939 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.93 · Expires 2023-05-14	Direct	0	Reported balance After 2020-11-11 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2020-11-11 · Disposition to issuer · Disposed 144,625 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.55 · Expires 2023-04-17	Direct	0	Reported balance After 2020-11-11 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2020-11-11 · Disposition to issuer · Disposed 9,771 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.75 · Expires 2022-05-09	Direct	0	Reported balance After 2020-11-11 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2020-11-11 · Disposition to issuer · Disposed 145,500 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.70 · Expires 2022-04-16	Direct	0	Reported balance After 2020-11-11 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2020-11-11 · Disposition to issuer · Disposed 4,112 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.55 · Expires 2021-09-17	Direct	0	Reported balance After 2020-11-11 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2020-11-11 · Disposition to issuer · Disposed 483,849 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 863,885 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).

F2: Includes 83,646 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 160,716 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See notes (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer.

F3: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer.

F4: Includes 83,646 Shares issuable upon vesting of the Wright RSUs and 12,329 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer.

F5: See Exhibit 99.1

F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes.

F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 17, 2026 Filed Jun 18, 2026 20:10 UTC	RxSight, Inc. RXST · Entity 1226	GrantCommon Stock	37,037	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-275851 · ownership.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,076 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document
June 17, 2026 Filed Jun 22, 2026 22:20 UTC	AEON Biopharma, Inc. AEON · Entity 7859	GrantClass A Common Stock	222,684	$0.00	$0.00	Disclosure SEC source: 0001104659-26-076513 · tm2618486-4_4seq1.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 258,705 F1 · security: Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date. F1 · price: Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date. Read SEC document
June 03, 2025 Filed Jun 5, 2025 01:35 UTC	RxSight, Inc. RXST · Entity 1226	GrantCommon Stock	10,752	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-081957 · ownership.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,039 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 3, 2025. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document
May 21, 2025 Filed May 23, 2025 20:51 UTC	AEON Biopharma, Inc. AEON · Entity 7859	GrantRestricted Stock Units · Derivative	308,641	$0.00	$0.00	Disclosure SEC source: 0001610717-25-000132 · form4.xml · derivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,641 Underlying: Class A Common Stock · 308,641 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date. F2 · derivative.exercise_date: 100% of the RSUs shall vest in full on the one year anniversary of May 21, 2025. F2 · derivative.expiration_date: 100% of the RSUs shall vest in full on the one year anniversary of May 21, 2025. Read SEC document
August 31, 2024 Filed Sep 5, 2024 01:49 UTC	AEON Biopharma, Inc. AEON · Entity 7859	GrantStock Option · Derivative	96,210	$0.00 Strike: $0.83	$0.00	Disclosure SEC source: 0001104659-24-097059 · tm2423415-6_4seq1.xml · derivative · entry 2 PALMISANO ROBERT J · CIK 0001138646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,210 Underlying: Class A Common Stock · 96,210 shares Expires 2034-08-30 F2 · shares: Represents an award of stock options granted on August 31, 2024 (the "Grant Date"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. F2 · derivative.exercise_date: Represents an award of stock options granted on August 31, 2024 (the "Grant Date"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document
August 31, 2024 Filed Sep 5, 2024 01:49 UTC	AEON Biopharma, Inc. AEON · Entity 7859	GrantClass A Common Stock	36,021	$0.00	$0.00	Disclosure SEC source: 0001104659-24-097059 · tm2423415-6_4seq1.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,021 F1 · price: Represents an award of restricted stock units granted on August 31, 2024 (the "Grant Date"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document
August 31, 2024 Filed Sep 11, 2024 01:04 UTC Amendment	AEON Biopharma, Inc. AEON · Entity 7859	GrantClass A Common Stock	36,021	$0.00	$0.00	Disclosure SEC source: 0001104659-24-098707 · tm2423757-1_4aseq1.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,021 F1 · price: Represents an award of restricted stock units granted on August 31, 2024 (the "Grant Date"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document
June 06, 2024 Filed Jun 10, 2024 20:23 UTC	RxSight, Inc. RXST · Entity 1226	GrantCommon Stock	2,554	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-071320 · ownership.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,287 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 6, 2024. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document
March 19, 2024 Filed Mar 21, 2024 23:51 UTC	AEON Biopharma, Inc. AEON · Entity 7859	GrantStock Option · Derivative	16,260	$0.00 Strike: $14.40	$0.00	Disclosure SEC source: 0001104659-24-037439 · tm249503-6_4seq1.xml · derivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,260 Underlying: Common Stock · 16,260 shares Expires 2034-03-18 F1 · shares: Represents an award of stock options granted on March 19, 2024 (the "Grant Date"), which vests in substantially equal monthly installments over the one year following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Each option will vest in full upon a Change in Control (as defined in the AEON Biopharma Inc. 2023 Incentive Award Plan) of the Company. F1 · derivative.exercise_date: Represents an award of stock options granted on March 19, 2024 (the "Grant Date"), which vests in substantially equal monthly installments over the one year following the Grant Date, subject to the reporting person's continued service through the applicable vesting date. Each option will vest in full upon a Change in Control (as defined in the AEON Biopharma Inc. 2023 Incentive Award Plan) of the Company. Read SEC document
August 14, 2023 Filed Aug 16, 2023 20:06 UTC	AEON Biopharma, Inc. AEON · Entity 7859	GrantStock Option · Derivative	58,851	$0.00 Strike: $5.47	$0.00	Disclosure SEC source: 0001104659-23-092548 · tm2323956-3_4seq1.xml · derivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,851 Underlying: Common Stock · 58,851 shares Expires 2033-08-13 F1 · shares: Represents an award of stock options on August 14, 2023, which vests in three yearly installments from August 14, 2023, subject to the reporting person's continued service through the applicable vesting date. F1 · derivative.exercise_date: Represents an award of stock options on August 14, 2023, which vests in three yearly installments from August 14, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document
July 21, 2023 Filed Jul 26, 2023 21:06 UTC	AEON Biopharma, Inc. AEON · Entity 7859	ConversionRestricted Stock Units · Derivative	77,453	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-010810 · dp197251_4-psllc.xml · derivative · entry 11 Priveterra Sponsor, LLC · CIK 0001843128 · 10% owner Grodnensky Oleg · CIK 0001843167 · 10% owner PALMISANO ROBERT J · CIK 0001138646 · Director · 10% owner Malik Vikram · CIK 0001730123 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Vikram Malik Disclosed balance after: 77,453 Underlying: Stock Options · 77,453 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_price: At the Effective Time, each outstanding award of restricted stock unit ("RSU") representing the contingent right to receive shares of AEON common stock (each an "AEON RSU") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole share. F15 · derivative.exercise_price: Represents an award of RSUs on April 26, 2023, which vests 6.25% vests upon the achievement of a first earnout goal, 25% upon the achievement of a second earnout goal, 25% upon the achievement of a third earnout, and 43.75% upon achievement of a fourth earnout goal. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F14 · shares: At the Effective Time, each outstanding award of restricted stock unit ("RSU") representing the contingent right to receive shares of AEON common stock (each an "AEON RSU") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole share. F15 · shares: Represents an award of RSUs on April 26, 2023, which vests 6.25% vests upon the achievement of a first earnout goal, 25% upon the achievement of a second earnout goal, 25% upon the achievement of a third earnout, and 43.75% upon achievement of a fourth earnout goal. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F15 · price: Represents an award of RSUs on April 26, 2023, which vests 6.25% vests upon the achievement of a first earnout goal, 25% upon the achievement of a second earnout goal, 25% upon the achievement of a third earnout, and 43.75% upon achievement of a fourth earnout goal. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F15 · derivative.exercise_date: Represents an award of RSUs on April 26, 2023, which vests 6.25% vests upon the achievement of a first earnout goal, 25% upon the achievement of a second earnout goal, 25% upon the achievement of a third earnout, and 43.75% upon achievement of a fourth earnout goal. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F15 · derivative.expiration_date: Represents an award of RSUs on April 26, 2023, which vests 6.25% vests upon the achievement of a first earnout goal, 25% upon the achievement of a second earnout goal, 25% upon the achievement of a third earnout, and 43.75% upon achievement of a fourth earnout goal. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Read SEC document
July 21, 2023 Filed Jul 26, 2023 21:06 UTC	AEON Biopharma, Inc. AEON · Entity 7859	ConversionStock Options · Derivative	7,765	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-010810 · dp197251_4-psllc.xml · derivative · entry 10 Priveterra Sponsor, LLC · CIK 0001843128 · 10% owner Grodnensky Oleg · CIK 0001843167 · 10% owner PALMISANO ROBERT J · CIK 0001138646 · Director · 10% owner Malik Vikram · CIK 0001730123 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Vikram Malik Disclosed balance after: 7,765 Underlying: Stock Options · 7,765 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer at a per-share exercise price of $10 per share. F13 · shares: Represents an award of stock options granted on March 9, 2022, which vests in three yearly installments from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F13 · price: Represents an award of stock options granted on March 9, 2022, which vests in three yearly installments from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F12 · derivative.exercise_date: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F12 · derivative.expiration_date: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Read SEC document
July 21, 2023 Filed Jul 26, 2023 21:06 UTC	AEON Biopharma, Inc. AEON · Entity 7859	ConversionStock Options · Derivative	21,198	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-010810 · dp197251_4-psllc.xml · derivative · entry 9 Priveterra Sponsor, LLC · CIK 0001843128 · 10% owner Grodnensky Oleg · CIK 0001843167 · 10% owner PALMISANO ROBERT J · CIK 0001138646 · Director · 10% owner Malik Vikram · CIK 0001730123 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Vikram Malik Disclosed balance after: 21,198 Underlying: Stock Options · 21,198 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer at a per-share exercise price of $10 per share. F12 · shares: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F12 · price: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F12 · derivative.exercise_date: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F12 · derivative.expiration_date: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Read SEC document
July 21, 2023 Filed Jul 26, 2023 21:06 UTC	AEON Biopharma, Inc. AEON · Entity 7859	ConversionStock Options · Derivative	19,800	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-010810 · dp197251_4-psllc.xml · derivative · entry 8 Priveterra Sponsor, LLC · CIK 0001843128 · 10% owner Grodnensky Oleg · CIK 0001843167 · 10% owner PALMISANO ROBERT J · CIK 0001138646 · Director · 10% owner Malik Vikram · CIK 0001730123 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Vikram Malik Disclosed balance after: 19,800 Underlying: Stock Options · 19,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer at a per-share exercise price of $10 per share. F11 · shares: Represents an award of stock options granted on March 5, 2021, which vested ratably over one year from March 5, 2021. Such options expire on March 5, 2031. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F11 · price: Represents an award of stock options granted on March 5, 2021, which vested ratably over one year from March 5, 2021. Such options expire on March 5, 2031. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F12 · derivative.exercise_date: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F12 · derivative.expiration_date: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Read SEC document
July 21, 2023 Filed Jul 26, 2023 21:06 UTC	AEON Biopharma, Inc. AEON · Entity 7859	ConversionStock Options · Derivative	21,974	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-010810 · dp197251_4-psllc.xml · derivative · entry 7 Priveterra Sponsor, LLC · CIK 0001843128 · 10% owner Grodnensky Oleg · CIK 0001843167 · 10% owner PALMISANO ROBERT J · CIK 0001138646 · Director · 10% owner Malik Vikram · CIK 0001730123 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Vikram Malik Disclosed balance after: 21,974 Underlying: Stock Options · 21,974 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer at a per-share exercise price of $10 per share. F10 · shares: Represents an award of stock options granted on August 5, 2020, which vested ratably over one year from March 4, 2020. Such options expire on August 1, 2030. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F10 · price: Represents an award of stock options granted on August 5, 2020, which vested ratably over one year from March 4, 2020. Such options expire on August 1, 2030. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F12 · derivative.exercise_date: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F12 · derivative.expiration_date: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Read SEC document
July 21, 2023 Filed Jul 26, 2023 21:06 UTC	AEON Biopharma, Inc. AEON · Entity 7859	ConversionStock Options · Derivative	38,824	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-010810 · dp197251_4-psllc.xml · derivative · entry 6 Priveterra Sponsor, LLC · CIK 0001843128 · 10% owner Grodnensky Oleg · CIK 0001843167 · 10% owner PALMISANO ROBERT J · CIK 0001138646 · Director · 10% owner Malik Vikram · CIK 0001730123 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Vikram Malik Disclosed balance after: 38,824 Underlying: Stock Options · 38,824 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer at a per-share exercise price of $10 per share. F9 · shares: Represents an award of stock options granted on November 20, 2019, which vested in three yearly installments from November 1, 2019. Such options expire on November 20, 2029. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F9 · price: Represents an award of stock options granted on November 20, 2019, which vested in three yearly installments from November 1, 2019. Such options expire on November 20, 2029. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F12 · derivative.exercise_date: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F12 · derivative.expiration_date: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Read SEC document
July 21, 2023 Filed Jul 26, 2023 21:06 UTC	AEON Biopharma, Inc. AEON · Entity 7859	ConversionStock Options · Derivative	38,824	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-010810 · dp197251_4-psllc.xml · derivative · entry 5 Priveterra Sponsor, LLC · CIK 0001843128 · 10% owner Grodnensky Oleg · CIK 0001843167 · 10% owner PALMISANO ROBERT J · CIK 0001138646 · Director · 10% owner Malik Vikram · CIK 0001730123 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Oleg Grodnensky Disclosed balance after: 38,824 Underlying: Stock Options · 38,824 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer at a per-share exercise price of $10 per share. F9 · shares: Represents an award of stock options granted on November 20, 2019, which vested in three yearly installments from November 1, 2019. Such options expire on November 20, 2029. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F9 · price: Represents an award of stock options granted on November 20, 2019, which vested in three yearly installments from November 1, 2019. Such options expire on November 20, 2029. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F12 · derivative.exercise_date: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. F12 · derivative.expiration_date: Represents an award of stock options granted on March 9, 2022, which vested ratably over one year from March 9, 2022. Such options expire on March 9, 2032. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Read SEC document
July 21, 2023 Filed Jul 26, 2023 21:06 UTC	AEON Biopharma, Inc. AEON · Entity 7859	GrantPrivate Placement Warrants · Derivative	5,280,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-010810 · dp197251_4-psllc.xml · derivative · entry 4 Priveterra Sponsor, LLC · CIK 0001843128 · 10% owner Grodnensky Oleg · CIK 0001843167 · 10% owner PALMISANO ROBERT J · CIK 0001138646 · Director · 10% owner Malik Vikram · CIK 0001730123 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,280,000 shares Expires not disclosed F3 · derivative.exercise_price: As described in the Issuer's Registration Statement on Form S-1 (File No. 333-252310) filed with the Securities and Exchange Commission on January 21, 2021, the Private Placement Warrants are identical to the warrants sold in connection with the Issuer's IPO, except that (i) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days after the completion of the Initial Business Combination (except, among other limited exceptions, to Priveterra's officers and directors, the Sponsor, or any of its or their respective permitted transferees); F4 · derivative.exercise_price: (ii) the Private Placement Warrants will not be redeemable by the Issuer so long as they are held by the Sponsor, Priveterra's officers or directors, or its or their respective permitted transferees (except as set forth in the warrant agreement), (iii) the Private Placement Warrants may be exercised by the Sponsor, Priveterra's officers and directors, or its or their respective permitted transferees on a cashless basis, (iv) if the private placement warrants are held by holders other than the Sponsor, Priveterra's officers and directors, or its or their permitted transferees, the Private Placement Warrants will be redeemable by the Issuer and exercisable by the holders on the same basis as the public warrants; and (v) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) are entitled to registration rights. F3 · price: As described in the Issuer's Registration Statement on Form S-1 (File No. 333-252310) filed with the Securities and Exchange Commission on January 21, 2021, the Private Placement Warrants are identical to the warrants sold in connection with the Issuer's IPO, except that (i) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days after the completion of the Initial Business Combination (except, among other limited exceptions, to Priveterra's officers and directors, the Sponsor, or any of its or their respective permitted transferees); F4 · price: (ii) the Private Placement Warrants will not be redeemable by the Issuer so long as they are held by the Sponsor, Priveterra's officers or directors, or its or their respective permitted transferees (except as set forth in the warrant agreement), (iii) the Private Placement Warrants may be exercised by the Sponsor, Priveterra's officers and directors, or its or their respective permitted transferees on a cashless basis, (iv) if the private placement warrants are held by holders other than the Sponsor, Priveterra's officers and directors, or its or their permitted transferees, the Private Placement Warrants will be redeemable by the Issuer and exercisable by the holders on the same basis as the public warrants; and (v) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) are entitled to registration rights. F3 · derivative.exercise_date: As described in the Issuer's Registration Statement on Form S-1 (File No. 333-252310) filed with the Securities and Exchange Commission on January 21, 2021, the Private Placement Warrants are identical to the warrants sold in connection with the Issuer's IPO, except that (i) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days after the completion of the Initial Business Combination (except, among other limited exceptions, to Priveterra's officers and directors, the Sponsor, or any of its or their respective permitted transferees); F4 · derivative.exercise_date: (ii) the Private Placement Warrants will not be redeemable by the Issuer so long as they are held by the Sponsor, Priveterra's officers or directors, or its or their respective permitted transferees (except as set forth in the warrant agreement), (iii) the Private Placement Warrants may be exercised by the Sponsor, Priveterra's officers and directors, or its or their respective permitted transferees on a cashless basis, (iv) if the private placement warrants are held by holders other than the Sponsor, Priveterra's officers and directors, or its or their permitted transferees, the Private Placement Warrants will be redeemable by the Issuer and exercisable by the holders on the same basis as the public warrants; and (v) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) are entitled to registration rights. F3 · derivative.expiration_date: As described in the Issuer's Registration Statement on Form S-1 (File No. 333-252310) filed with the Securities and Exchange Commission on January 21, 2021, the Private Placement Warrants are identical to the warrants sold in connection with the Issuer's IPO, except that (i) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days after the completion of the Initial Business Combination (except, among other limited exceptions, to Priveterra's officers and directors, the Sponsor, or any of its or their respective permitted transferees); F4 · derivative.expiration_date: (ii) the Private Placement Warrants will not be redeemable by the Issuer so long as they are held by the Sponsor, Priveterra's officers or directors, or its or their respective permitted transferees (except as set forth in the warrant agreement), (iii) the Private Placement Warrants may be exercised by the Sponsor, Priveterra's officers and directors, or its or their respective permitted transferees on a cashless basis, (iv) if the private placement warrants are held by holders other than the Sponsor, Priveterra's officers and directors, or its or their permitted transferees, the Private Placement Warrants will be redeemable by the Issuer and exercisable by the holders on the same basis as the public warrants; and (v) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) are entitled to registration rights. Read SEC document
July 21, 2023 Filed Jul 26, 2023 21:06 UTC	AEON Biopharma, Inc. AEON · Entity 7859	ConversionClass B Common Stock · Derivative	6,900,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-010810 · dp197251_4-psllc.xml · derivative · entry 3 Priveterra Sponsor, LLC · CIK 0001843128 · 10% owner Grodnensky Oleg · CIK 0001843167 · 10% owner PALMISANO ROBERT J · CIK 0001138646 · Director · 10% owner Malik Vikram · CIK 0001730123 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,900,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Priveterra Acquisition Corp. ("Priveterra") Class B common stock were cancelled and, in exchange, the holder(s) thereof was entitled to receive Class A common stock of the Issuer on a one-for-one basis upon the consummation of the Issuer's initial business combination on July 21, 2023 pursuant to that certain Business Combination Agreement (the "BCA"), dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("Old AEON") (the "Initial Business Combination"). 2,070,000 of the shares of Class A common stock of the Issuer held by Priveterra Sponsor, LLC. (the "Sponsor") are fully vested. F2 · derivative.exercise_price: 1,380,000 of the shares of Class A common stock of the Issuer held by the Sponsor vest based on the achievement of certain pre-established share price targets and the remaining 3,450,000 shares of Class A common stock of the Issuer held by the Sponsor will vest based on the achievement of certain milestones, each as set forth in Amendment No.1 to the Sponsor Support Agreement, dated as of April 27, 2023. Simultaneously with the Issuer's initial public offering ("IPO"), the Sponsor acquired 5,213,333 warrants of the Issuer exercisable to purchase one share of Class A common stock of the Issuer at an exercise price of $11.50 per share (the "Private Placement Warrants") and Sponsor subsequently acquired 66,667 Private Placement Warrants on June 28, 2021 upon the conversion of an unsecured convertible promissory note issued by the Issuer to the Sponsor on February 15, 2021. F7 · shares: The reporting person disposed of all Class B common stock upon the consummation of the Issuer's Initial Business Combination, which were automatically exchanged on a one-for-one basis into Class A common stock of the Issuer. F1 · price: The Priveterra Acquisition Corp. ("Priveterra") Class B common stock were cancelled and, in exchange, the holder(s) thereof was entitled to receive Class A common stock of the Issuer on a one-for-one basis upon the consummation of the Issuer's initial business combination on July 21, 2023 pursuant to that certain Business Combination Agreement (the "BCA"), dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("Old AEON") (the "Initial Business Combination"). 2,070,000 of the shares of Class A common stock of the Issuer held by Priveterra Sponsor, LLC. (the "Sponsor") are fully vested. F2 · price: 1,380,000 of the shares of Class A common stock of the Issuer held by the Sponsor vest based on the achievement of certain pre-established share price targets and the remaining 3,450,000 shares of Class A common stock of the Issuer held by the Sponsor will vest based on the achievement of certain milestones, each as set forth in Amendment No.1 to the Sponsor Support Agreement, dated as of April 27, 2023. Simultaneously with the Issuer's initial public offering ("IPO"), the Sponsor acquired 5,213,333 warrants of the Issuer exercisable to purchase one share of Class A common stock of the Issuer at an exercise price of $11.50 per share (the "Private Placement Warrants") and Sponsor subsequently acquired 66,667 Private Placement Warrants on June 28, 2021 upon the conversion of an unsecured convertible promissory note issued by the Issuer to the Sponsor on February 15, 2021. F1 · derivative.exercise_date: The Priveterra Acquisition Corp. ("Priveterra") Class B common stock were cancelled and, in exchange, the holder(s) thereof was entitled to receive Class A common stock of the Issuer on a one-for-one basis upon the consummation of the Issuer's initial business combination on July 21, 2023 pursuant to that certain Business Combination Agreement (the "BCA"), dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("Old AEON") (the "Initial Business Combination"). 2,070,000 of the shares of Class A common stock of the Issuer held by Priveterra Sponsor, LLC. (the "Sponsor") are fully vested. F2 · derivative.exercise_date: 1,380,000 of the shares of Class A common stock of the Issuer held by the Sponsor vest based on the achievement of certain pre-established share price targets and the remaining 3,450,000 shares of Class A common stock of the Issuer held by the Sponsor will vest based on the achievement of certain milestones, each as set forth in Amendment No.1 to the Sponsor Support Agreement, dated as of April 27, 2023. Simultaneously with the Issuer's initial public offering ("IPO"), the Sponsor acquired 5,213,333 warrants of the Issuer exercisable to purchase one share of Class A common stock of the Issuer at an exercise price of $11.50 per share (the "Private Placement Warrants") and Sponsor subsequently acquired 66,667 Private Placement Warrants on June 28, 2021 upon the conversion of an unsecured convertible promissory note issued by the Issuer to the Sponsor on February 15, 2021. F1 · derivative.expiration_date: The Priveterra Acquisition Corp. ("Priveterra") Class B common stock were cancelled and, in exchange, the holder(s) thereof was entitled to receive Class A common stock of the Issuer on a one-for-one basis upon the consummation of the Issuer's initial business combination on July 21, 2023 pursuant to that certain Business Combination Agreement (the "BCA"), dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("Old AEON") (the "Initial Business Combination"). 2,070,000 of the shares of Class A common stock of the Issuer held by Priveterra Sponsor, LLC. (the "Sponsor") are fully vested. F2 · derivative.expiration_date: 1,380,000 of the shares of Class A common stock of the Issuer held by the Sponsor vest based on the achievement of certain pre-established share price targets and the remaining 3,450,000 shares of Class A common stock of the Issuer held by the Sponsor will vest based on the achievement of certain milestones, each as set forth in Amendment No.1 to the Sponsor Support Agreement, dated as of April 27, 2023. Simultaneously with the Issuer's initial public offering ("IPO"), the Sponsor acquired 5,213,333 warrants of the Issuer exercisable to purchase one share of Class A common stock of the Issuer at an exercise price of $11.50 per share (the "Private Placement Warrants") and Sponsor subsequently acquired 66,667 Private Placement Warrants on June 28, 2021 upon the conversion of an unsecured convertible promissory note issued by the Issuer to the Sponsor on February 15, 2021. F5 · balance_after: The Sponsor is the record holder of the securities reported herein. Messrs Grodnensky, Palmisano, and Malik are the managers of the Sponsor and share voting and investment discretion with respect to the securities held of record by the Sponsor. Read SEC document
July 21, 2023 Filed Jul 26, 2023 21:06 UTC	AEON Biopharma, Inc. AEON · Entity 7859	ConversionClass A Common Stock	89,163	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-010810 · dp197251_4-psllc.xml · nonDerivative · entry 2 Priveterra Sponsor, LLC · CIK 0001843128 · 10% owner Grodnensky Oleg · CIK 0001843167 · 10% owner PALMISANO ROBERT J · CIK 0001138646 · Director · 10% owner Malik Vikram · CIK 0001730123 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Vikram Malik Disclosed balance after: 6,989,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Priveterra Acquisition Corp. ("Priveterra") Class B common stock were cancelled and, in exchange, the holder(s) thereof was entitled to receive Class A common stock of the Issuer on a one-for-one basis upon the consummation of the Issuer's initial business combination on July 21, 2023 pursuant to that certain Business Combination Agreement (the "BCA"), dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("Old AEON") (the "Initial Business Combination"). 2,070,000 of the shares of Class A common stock of the Issuer held by Priveterra Sponsor, LLC. (the "Sponsor") are fully vested. F2 · price: 1,380,000 of the shares of Class A common stock of the Issuer held by the Sponsor vest based on the achievement of certain pre-established share price targets and the remaining 3,450,000 shares of Class A common stock of the Issuer held by the Sponsor will vest based on the achievement of certain milestones, each as set forth in Amendment No.1 to the Sponsor Support Agreement, dated as of April 27, 2023. Simultaneously with the Issuer's initial public offering ("IPO"), the Sponsor acquired 5,213,333 warrants of the Issuer exercisable to purchase one share of Class A common stock of the Issuer at an exercise price of $11.50 per share (the "Private Placement Warrants") and Sponsor subsequently acquired 66,667 Private Placement Warrants on June 28, 2021 upon the conversion of an unsecured convertible promissory note issued by the Issuer to the Sponsor on February 15, 2021. F6 · ownership.direct: These securities, which were acquired upon the closing of the Initial Business Combination pursuant to the terms of the BCA as a result of the cancellation of the shares of Old AEON ("Old AEON Common Stock") held by Mr. Malik and Sabina Taneja and the automatic conversion of such shares into 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer, are held directly by Mr. Malik, a manager of the Sponsor, and Ms. Taneja. The Sponsor disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Read SEC document
July 21, 2023 Filed Jul 26, 2023 21:06 UTC	AEON Biopharma, Inc. AEON · Entity 7859	ConversionClass A Common Stock	6,900,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950103-23-010810 · dp197251_4-psllc.xml · nonDerivative · entry 1 Priveterra Sponsor, LLC · CIK 0001843128 · 10% owner Grodnensky Oleg · CIK 0001843167 · 10% owner PALMISANO ROBERT J · CIK 0001138646 · Director · 10% owner Malik Vikram · CIK 0001730123 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,900,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Priveterra Acquisition Corp. ("Priveterra") Class B common stock were cancelled and, in exchange, the holder(s) thereof was entitled to receive Class A common stock of the Issuer on a one-for-one basis upon the consummation of the Issuer's initial business combination on July 21, 2023 pursuant to that certain Business Combination Agreement (the "BCA"), dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("Old AEON") (the "Initial Business Combination"). 2,070,000 of the shares of Class A common stock of the Issuer held by Priveterra Sponsor, LLC. (the "Sponsor") are fully vested. F2 · price: 1,380,000 of the shares of Class A common stock of the Issuer held by the Sponsor vest based on the achievement of certain pre-established share price targets and the remaining 3,450,000 shares of Class A common stock of the Issuer held by the Sponsor will vest based on the achievement of certain milestones, each as set forth in Amendment No.1 to the Sponsor Support Agreement, dated as of April 27, 2023. Simultaneously with the Issuer's initial public offering ("IPO"), the Sponsor acquired 5,213,333 warrants of the Issuer exercisable to purchase one share of Class A common stock of the Issuer at an exercise price of $11.50 per share (the "Private Placement Warrants") and Sponsor subsequently acquired 66,667 Private Placement Warrants on June 28, 2021 upon the conversion of an unsecured convertible promissory note issued by the Issuer to the Sponsor on February 15, 2021. F3 · ownership.direct: As described in the Issuer's Registration Statement on Form S-1 (File No. 333-252310) filed with the Securities and Exchange Commission on January 21, 2021, the Private Placement Warrants are identical to the warrants sold in connection with the Issuer's IPO, except that (i) the Private Placement Warrants (including shares of Class A common stock issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days after the completion of the Initial Business Combination (except, among other limited exceptions, to Priveterra's officers and directors, the Sponsor, or any of its or their respective permitted transferees); Read SEC document
June 01, 2023 Filed Jun 5, 2023 20:35 UTC	RxSight, Inc. RXST · Entity 1226	GrantCommon Stock	5,731	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034333 · doc4.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,733 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 1, 2023. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document
June 02, 2022 Filed Jun 4, 2022 00:23 UTC	RxSight, Inc. RXST · Entity 1226	GrantCommon Stock	8,624	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034395 · doc4.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,002 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 2, 2022. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document
August 03, 2021 Filed Aug 5, 2021 23:18 UTC	RxSight, Inc. RXST · Entity 1226	GrantCommon Stock	7,645	$0.00	$0.00	Disclosure SEC source: 0000899243-21-031811 · doc4.xml · nonDerivative · entry 2 PALMISANO ROBERT J · CIK 0001138646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,378 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F3 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one third of the RSUs subject to the award shall vest on each annual anniversary of August 3, 2021. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document
August 03, 2021 Filed Aug 5, 2021 23:18 UTC	RxSight, Inc. RXST · Entity 1226	GrantCommon Stock	5,733	$0.00	$0.00	Disclosure SEC source: 0000899243-21-031811 · doc4.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,733 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the date immediately prior to the first annual meeting of stockholders following August 3, 2021. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	483,849	Not disclosed Strike: $15.55	Not disclosed	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · derivative · entry 18 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 483,849 shares Expires 2021-09-17 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	4,112	Not disclosed Strike: $17.70	Not disclosed	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · derivative · entry 17 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,112 shares Expires 2022-04-16 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	145,500	Not disclosed Strike: $20.75	Not disclosed	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · derivative · entry 16 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 145,500 shares Expires 2022-05-09 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	9,771	Not disclosed Strike: $22.55	Not disclosed	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · derivative · entry 15 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,771 shares Expires 2023-04-17 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	144,625	Not disclosed Strike: $23.93	Not disclosed	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · derivative · entry 14 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 144,625 shares Expires 2023-05-14 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	7,939	Not disclosed Strike: $30.14	Not disclosed	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · derivative · entry 13 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,939 shares Expires 2024-04-01 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	129,462	Not disclosed Strike: $29.06	Not disclosed	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · derivative · entry 12 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 129,462 shares Expires 2024-05-13 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	239,481	Not disclosed Strike: $20.62	Not disclosed	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · derivative · entry 11 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 239,481 shares Expires 2025-10-13 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	598,702	Not disclosed Strike: $20.62	Not disclosed	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · derivative · entry 10 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 598,702 shares Expires 2025-10-13 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	271,076	Not disclosed Strike: $21.42	Not disclosed	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · derivative · entry 9 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 271,076 shares Expires 2026-07-19 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	137,373	Not disclosed Strike: $27.86	Not disclosed	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · derivative · entry 8 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 137,373 shares Expires 2027-07-25 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	149,008	Not disclosed Strike: $24.49	Not disclosed	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · derivative · entry 7 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 149,008 shares Expires 2028-07-24 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	181,429	Not disclosed Strike: $27.84	Not disclosed	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · derivative · entry 6 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 181,429 shares Expires 2029-07-26 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerOrdinary Shares, par value EUR 0.03 per share	229,054	$30.75	$7,043,410.50	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · nonDerivative · entry 5 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F6 · kind: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	229,054	$0.00	$0.00	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · nonDerivative · entry 4 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,054 F6 · kind: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerOrdinary Shares, par value EUR 0.03 per share	95,975	$30.75	$2,951,231.25	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · nonDerivative · entry 3 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · kind: See Exhibit 99.1 Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerOrdinary Shares, par value EUR 0.03 per share	148,387	$0.00	$0.00	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · nonDerivative · entry 2 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,975 F3 · shares: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer. F4 · balance_after: Includes 83,646 Shares issuable upon vesting of the Wright RSUs and 12,329 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer. Read SEC document
November 11, 2020 Filed Nov 13, 2020 19:45 UTC	Wright Medical Group N.V. WMGI · Entity 145358	OtherOrdinary Shares, par value EUR 0.03 per share	863,885	$30.75	$26,564,463.75	Disclosure SEC source: 0001235802-20-000123 · primary_doc.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,362 F1 · kind: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 863,885 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). F2 · balance_after: Includes 83,646 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 160,716 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See notes (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer. Read SEC document
July 23, 2020 Filed Jul 27, 2020 20:01 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	160,716	$0.00	$0.00	Disclosure SEC source: 0001235802-20-000081 · primary_doc.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,108,247 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. The grant agreement contemplates that the shares will vest pro rata through the closing of the previously announced Stryker transaction, and shares unvested at closing will be cancelled. F2 · balance_after: Includes 64,919 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 219,707 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document
June 29, 2020 Filed Jul 1, 2020 20:16 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	93,066	$0.00	$0.00	Disclosure SEC source: 0001235802-20-000066 · primary_doc.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 947,531 F1 · shares: Represents the payout of a performance share unit award for the June 26, 2017 - June 28, 2020 performance period under the Wright Medical Group N.V. 2017 Equity and Incentive Plan, as approved by the Issuer's Compensation Committee of its Board of Directors. Performance share unit awards are paid in ordinary shares of the Issuer. F2 · balance_after: Includes 64,919 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 58,991 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document
March 13, 2020 Filed Mar 16, 2020 20:04 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GiftOrdinary Shares, par value EUR 0.03 per share	16,600	$0.00	$0.00	Disclosure SEC source: 0001235802-20-000021 · primary_doc.xml · nonDerivative · entry 2 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 854,465 F1 · balance_after: Includes 23,584 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan and 64,919 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 58,991 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document
March 09, 2020 Filed Mar 16, 2020 20:04 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GiftOrdinary Shares, par value EUR 0.03 per share	16,600	$0.00	$0.00	Disclosure SEC source: 0001235802-20-000021 · primary_doc.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 871,065 F1 · balance_after: Includes 23,584 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan and 64,919 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 58,991 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document
November 26, 2019 Filed Nov 27, 2019 21:27 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionStock Option (right to buy) · Derivative	145,000	$0.00 Strike: $15.55	$0.00	Disclosure SEC source: 0001235802-19-000138 · primary_doc.xml · derivative · entry 2 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,849 Underlying: Ordinary Shares · 145,000 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of a vested stock option in connection with 280G tax planning. F3 · derivative.exercise_date: This option has fully vested. Read SEC document
November 26, 2019 Filed Nov 27, 2019 21:27 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionOrdinary Shares, par value EUR 0.03 per share	145,000	$15.55	$2,254,750.00	Disclosure SEC source: 0001235802-19-000138 · primary_doc.xml · nonDerivative · entry 1 PALMISANO ROBERT J · CIK 0001138646 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 887,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of a vested stock option in connection with 280G tax planning. F2 · balance_after: Includes 23,584 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan and 64,919 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 58,991 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document
November 21, 2019 Filed Nov 25, 2019 21:32 UTC	AVEDRO INC AVDR · Entity 153528	Disposition to issuerRestricted Stock Units · Derivative	3,005	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-057939 · doc4.xml · derivative · entry 7 PALMISANO ROBERT J · CIK 0001138646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,005 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · price: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. F5 · derivative.exercise_date: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. F5 · derivative.expiration_date: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.